The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly

Sara Kollack-Walker; Collin Y Liu; Adam S Fleisher

doi:10.1016/j.ncl.2017.01.010

The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly

Neurol Clin. 2017 May;35(2):231-262. doi: 10.1016/j.ncl.2017.01.010.

Authors

Sara Kollack-Walker¹, Collin Y Liu², Adam S Fleisher³

Affiliations

¹ Scientific Comm, Global Med Comm - Bio-Medicines BU-NS, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: [email protected].
² Department of Neurology, Keck School of Medicine at the University of Southern California, 1520 San Pablo Street, HCC-2, Suite 3000, Los Angeles, CA 90033, USA.
³ Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

PMID: 28410658
DOI: 10.1016/j.ncl.2017.01.010

Abstract

This article reviews the current diagnostic tools that are available for structural, functional, and molecular imaging of the brain, summarizing some of the key findings that have been reported in individuals diagnosed with Alzheimer disease, mild cognitive impairment, prodromal AD, or other prevalent dementias. Given recent advances in the development of amyloid PET tracers, current guidelines for the use of amyloid PET imaging in patients with cognitive complaints are reviewed. In addition, data addressing the potential value of amyloid PET imaging in the clinical setting are highlighted.

Keywords: Brain imaging; CT; Dementia; MRI; PET; SPECT.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Aging*
Brain / diagnostic imaging*
Cognition Disorders / diagnostic imaging*
Dementia / diagnostic imaging*
Humans
Neuroimaging / methods*

Grants and funding

P50 AG005142/AG/NIA NIH HHS/United States